Randomised, double-blind, placebo-controlled trials of non-individualised homeopathic treatment: systematic review and meta-analysis

被引:82
|
作者
Mathie, Robert T. [1 ]
Ramparsad, Nitish [2 ]
Legg, Lynn A. [3 ]
Clausen, Juergen [4 ]
Moss, Sian [1 ]
Davidson, Jonathan R. T. [5 ]
Messow, Claudia-Martina [2 ]
McConnachie, Alex [2 ]
机构
[1] Homeopathy Res Inst, London, England
[2] Univ Glasgow, Inst Hlth & Wellbeing, Robertson Ctr Biostat, Glasgow, Lanark, Scotland
[3] Univ Strathclyde, Dept Biomed Engn, Glasgow, Lanark, Scotland
[4] Karl & Veronica Carstens Stiftung, Essen, Germany
[5] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA
关键词
Non-individualised homeopathy; Meta-analysis; Randomised controlled trials; Sensitivity analysis; Systematic review; PUBLICATION BIAS; EFFICACY; FILL; TRIM;
D O I
10.1186/s13643-017-0445-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: A rigorous systematic review and meta-analysis focused on randomised controlled trials (RCTs) of non-individualised homeopathic treatment has not previously been reported. We tested the null hypothesis that the main outcome of treatment using a non-individualised (standardised) homeopathic medicine is indistinguishable from that of placebo. An additional aim was to quantify any condition-specific effects of non-individualised homeopathic treatment. Methods: Literature search strategy, data extraction and statistical analysis all followed the methods described in a pre-published protocol. A trial comprised 'reliable evidence' if its risk of bias was low or it was unclear in one specified domain of assessment. 'Effect size' was reported as standardised mean difference (SMD), with arithmetic transformation for dichotomous data carried out as required; a negative SMD indicated an effect favouring homeopathy. Results: Forty-eight different clinical conditions were represented in 75 eligible RCTs. Forty-nine trials were classed as 'high risk of bias' and 23 as 'uncertain risk of bias'; the remaining three, clinically heterogeneous, trials displayed sufficiently low risk of bias to be designated reliable evidence. Fifty-four trials had extractable data: pooled SMD was -0.33 (95% confidence interval (CI) -0.44, -0.21), which was attenuated to -0.16 (95% CI -0.31, -0.02) after adjustment for publication bias. The three trials with reliable evidence yielded a non-significant pooled SMD: -0.18 (95% CI -0.46, 0.09). There was no single clinical condition for which meta-analysis included reliable evidence. Conclusions: The quality of the body of evidence is low. A meta-analysis of all extractable data leads to rejection of our null hypothesis, but analysis of a small sub-group of reliable evidence does not support that rejection. Reliable evidence is lacking in condition-specific meta-analyses, precluding relevant conclusions. Better designed and more rigorous RCTs are needed in order to develop an evidence base that can decisively provide reliable effect estimates of non-individualised homeopathic treatment.
引用
收藏
页数:28
相关论文
共 50 条
  • [31] Effect of Curcumin on Diabetic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Clinical Trials
    Jie, Zhao
    Chao, Mo
    Jun, Ai
    Wei, Shi
    Meng LiFeng
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2021, 2021
  • [32] Systematic Review on the Efficacy of Fexofenadine in Seasonal Allergic Rhinitis: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Clinical Trials
    Compalati, E.
    Baena-Cagnani, R.
    Penagos, M.
    Badellino, H.
    Braido, F.
    Gomez, R. M.
    Canonica, G. W.
    Baena-Cagnani, C. E.
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2011, 156 (01) : 1 - 15
  • [33] PLACEBO-CONTROLLED, DOUBLE-BLIND TRIALS
    KENT, GG
    LANCET, 1980, 1 (8182): : 1363 - 1364
  • [34] Ginkgo biloba for dementia -: A systematic review of double-blind, placebo-controlled trials
    Ernst, E
    Pittler, MH
    CLINICAL DRUG INVESTIGATION, 1999, 17 (04) : 301 - 308
  • [35] Ginkgo biloba for DementiaA Systematic Review of Double-Blind, Placebo-Controlled Trials
    E. Ernst
    M. H. Pittler
    Clinical Drug Investigation, 1999, 17 : 301 - 308
  • [36] Placebo-Controlled Trials in Surgery A Systematic Review and Meta-Analysis
    Probst, Pascal
    Grummich, Kathrin
    Harnoss, Julian C.
    Huettner, Felix J.
    Jensen, Katrin
    Braun, Silvia
    Kieser, Meinhard
    Ulrich, Alexis
    Buechler, Markus W.
    Diener, Markus K.
    MEDICINE, 2016, 95 (17)
  • [37] Estradiol and raloxifene as adjunctive treatment for women with schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials
    Li, Zijia
    Wang, Yucheng
    Wang, Zhe
    Kong, Lingtao
    Liu, Linzi
    Li, Liu
    Tang, Yanqing
    ACTA PSYCHIATRICA SCANDINAVICA, 2023, 147 (04) : 360 - 372
  • [38] Oral Pentasa in the Treatment of Active Crohn's Disease: A Meta-Analysis of Double-Blind, Placebo-Controlled Trials
    Hanauer, Stephen B.
    Stromberg, Ulf
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (05) : 379 - 388
  • [39] Meta-analysis of randomized, double-blind, placebo-controlled trials of melatonin in Alzheimer's disease
    Wang, Yuan-Yuan
    Zheng, Wei
    Ng, Chee H.
    Ungvari, Gabor S.
    Wei, Wei
    Xiang, Yu-Tao
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2017, 32 (01) : 50 - 57
  • [40] Herbal Medicine Formulas for Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Double-Blind Placebo-Controlled Clinical Trials
    Shan, Chun-Shuo
    Zhang, Hong-Feng
    Xu, Qing-Qing
    Shi, Yi-Hua
    Wang, Yong
    Li, Yan
    Lin, Yan
    Zheng, Guo-Qing
    FRONTIERS IN AGING NEUROSCIENCE, 2018, 10